AZN : Phase III Trial Of Imfinzi On Recurrent Or Metastatic Head & Neck Cancer Fails To Meet Goal

(RTTNews) – AstraZeneca Plc. (AZN.L, AZN) said that a late-stage trial of Imfinzi with or without tremelimumab in the 1st-line treatment of recurrent or metastatic head and neck cancer did not meet the primary as well as secondary endpoints.As per the Kestrel Phase III trial resuRead MoreMarketsMarkets Feed